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INTRODUCTION
Extended spectrum beta-lactamase (ESBL)-producing Gram-negative bacteria have been a major cause of hospital-acquired infections since the mid-1980s (Paterson and Bonomo, 2005) and thus the main reason for the clinical use of broad spectrum antibiotics, including cephalosporins and monobactams (Knothe et al., 1983; Hoffmann et al., 2006; Paberza et al., 2007) .
Infections caused by ESBL-producing microorganisms vary from urinary tract infections to severe sepsis, with the most typical representatives of Enterobacteriaceae family involved (Deepti and Deepti, 2010) . This taxonomic group includes Escherichia coli, Klebsiella pneumoniae and Enterobacter cloacae. Other authors mention Proteus mirabilis (Cohen-Nahum et al., 2010) . These bacteria can be found in nosocomial settings and also in the community (Zahar et al., 2015) . The major risk factors for infection with ESBLproducing microorganisms include prolonged hospital stay, antibacterial therapy, invasive procedures, severe comorbidities, immunosuppression and intra-abdominal surgery (Asir et al., 2015) .
According to the European Center of Disease Control Surveillance 2013 report, in Latvia approximately 50% of K. pneumoniae and 10-25% of E. coli are ESBL producers (Anonymous, 2013) .
ESBL-producing bacteria associated with infections in Latvia are found most frequently in the digestive tract system (Skuja et al., 2015) . However, the presence of ESBLproducing bacteria in gut microbiota in the hospital has been poorly studied in Latvia. The risk of being infected by PROCEEDINGS OF THE LATVIAN ACADEMY OF SCIENCES. Section B, Vol. 73 (2019) The aim of the present study was to determine the frequency of ESBL-producing bacteria among the Enterobacteriaceae in patients at two Latvian surgical profile wards of Rîga East University on admission and on discharge. One of the wards specialises in soft tissue infections including diabetic foot and the other in the treatment of burns. We determined correlation between the acquisition of ESBL bacteria and duration of stay in hospital; therefore, we determined the prevalence of ESBL in faeces for patients both at admission and at discharge from hospital. Also, we aimed to analyse the etiological spectrum of surgical site infections (SSI) and its correlation to ESBL prevalence in gut.
MATERIALS AND METHODS
The retrospective study was conducted at Rîga East University Hospital (REUH Clinical and microbiological data were recorded for 136 patients admitted into surgical and burn wards, from whom faecal and wound samples were collected. Culture isolates were obtained from patient gut microbiota at admission and on discharge from the hospital. Bacterial samples were collected using swabs from wounds and rectum.
A VITEK ® 2 automated system (Biomerieux, France) was used for microbial identification (Spanu et al., 2003) . All 136 bacterial isolates were screened for the presence of ESBL-producing bacteria using the double disk diffusion method and determination of minimum inhibitory concentration (MIC) method (for P. mirabilis) according to Clinical and Laboratory Standards Institute (CLSI-2017-M100-S27). The ceftazidime and cefotaxime double disk method is a standard marker used for determination of ESBLproducing bacteria (Jarlier et al., 1998) . For bacterial susceptibility testing, the disk diffusion method with the following antibacterial disks was used: cefotaxime (30 µg), ceftriaxone (30 µg), ceftazidime (30 µg), gentamicin (10 µg), amikacin (30 µg), ampicillin (10 µg), ciprofloxacin (5 µg), levofloxacin (10 µg), trimethoprim-sulfamethoxazole (1.25/23.75 µg), meropenem (10 µg) and imipenem (10 µg).
RESULTS
ESBL-producing bacteria were collected twice from 136 patients -upon admission and on discharge from the hospital. In total, 46 (33.8%) from 136 patients were ESBL positive and ESBL was found to be positive for 51 bacterial isolates.
The duration of ESBL-positive inpatient stay was from 1 to 47 days; on average patients spent 11 days at the hospital, with modal value 6 days. The largest number of patients (14) spent 6-10 days in the hospital (Fig. 1 ). There were nine newly acquired ESBL-positive patients. Six patients spent from one to five days at the hospital, another ten patients spent approximately two weeks at the hospital, and four patients had a longer duration of hospitalisationmore than 25 days. Twenty-five of the 136 patients were ESBL-positive and repeatedly hospitalised.
In order to show the risk of acquiring ESBL-producing bacteria in gut microbiota due to hospitalisation, we compared ESBL-positive microbiota versus ESBL-negative microbiota on the day of the admission to the hospital and on the day of the discharge. Our results showed negative tendency for ESBL colonisation. Twenty-one (15.4%) of 136 patients were ESBL positive on admission, and 115 (84.6%) were ESBL negative at admission. Twenty-five patients had gained ESBL-positive microbiota by the time of discharge from hospital; therefore, in total, 45 patients were ESBLpositive on discharge from the hospital (Table 1) . This group indicates the increased risk of acquiring ESBLproducing bacteria during a stay in closed environment. Interestingly, one patient was ESBL-positive upon admission in a hospital, but negative on discharge from hospital, indicating loss of ESBL-producing bacteria from the intestinal tract. Representatives of three genera of Enterobacteriaceae family, namely, Klebsiella, Escherichia and Proteus, were identified and tested for ESBL production. On discharge from hospital, K. pneumoniae (n = 24) was the most frequently isolated ESBL-producing bacteria species from 51 ESBL-positive isolates (faecal samples), followed by E. coli (n = 19;) and P. mirabilis (n = 8) ( Table 2 , Fig. 2 ). Polymicrobial flora was detected in five (9.8%) isolates.
There was an increase in frequency of K. pneumoniae from 22.2% to 88.9% between admission and on discharge from hospital. Also, the number of cases of ESBL-positive P. mirabilis and E. coli increased on discharge from hospital, respectively, 100.0% and 13.2%.
All bacterial isolates were tested for antibacterial susceptibility by conventional susceptibility testing. Antimicrobial susceptibility of ESBL-positive Enterobacteriaceae family bacteria is shown in Figure 3 . Antibiograms showed that all tested bacteria were susceptible to carbapenems (meropenem and imipenem), but were completely resistant to cephalosporins (100.0%). Also, most of the bacterial isolates exhibited resistance to trimethoprim-sulfamethoxazole (n = 44; 86.3%) and to gentamicin (n = 34; 66.7%). In seven cases (13.7%) susceptibility to ciprofloxacin was evaluated as intermediate, as shown in Figure 3 .
Mostly representatives of Enterobacteriaceae family were identified among those isolated from gut and wound infections. Of the ESBL-positive bacteria, the most frequent were E. coli (n = 19; 7.0%), K. pneumoniae (n = 24; 47.1%), followed by P. mirabilis (n = 8; 5.0%). The proportion of these species was lower in wounds -K. pneumoniae (n = 1; 1.9%), E. coli and P. mirabilis (n = 2; 3.7%). No ESBL positive isolates were identified in wound infections.
No methicillin-resistant Staphylococcus aureus (MRSA) and coagulase-negative Staphylococci species were found in gut microbiota. However, coagulase-negative staphylococci (CoNS) were predominant (n = 10; 18.5%) in wound microbiota, followed by Pseudomonas aeruginosa (n = 6; 11.1%) and MRSA (n = 2; 3.7%).
Wound infection was diagnosed in 26 (58.7%) of 46 ESBL patients. The most commonly isolated bacteria from wound infections were S. aureus (n = 8, 23.7%), CoNS (n = 6, 15.8%) and methicillin-resistant Staphylococcus aureus (MRSA) (n = 5, 13.2%). Ten (n = 10, 26.9%) bacterial isolates belonged to polymicrobial microbiota, including S. aureus, MRSA, CoNS, P. aeruginosa etc. In this group, only two species of the Enterobacteriaceae family (P. mirabilis and K. pneumonia) were identified. None of them were identified as ESBL-producing bacteria, as shown in Figure  4 .
For inpatients with ESBL-producing bacteria, the main reasons of hospitalisation were burns, frostbites, bedsores, and type 2 diabetes mellitus with complications such as diabetic foot and gangrene. Diabetic foot infection was diagnosed in eight cases. Surgeries were performed on 13 patients during the hospitalisation period. Twenty-five of the patients had to be re-admitted due to complications (data not shown). On discharge* 24 (88.9%) 18(13.2%) 8 (100.0%) 0 (0%) 1(5.6%) 0 (0%) *Including one patient who was ESBL-positive at admission and was ESBL-negative on the day of discharge from hospital. The most common bacterial species detected in wounds of ESBL-positive patients were S. aureus (n = 9; 23.7%), CoNS (n = 6; 15.8%), MRSA (n = 5; 13.2%), P. mirabilis (n = 4; 10.5%), A. baumannii (n = 3; 7.9%), P. aeruginosa (n = 3; 7.9%), and M. morganii (n = 2; 5.3%). Bacterial species, isolated only once were as follows: P. vulgaris, E. coli, H. alvei, E. amnigenus, K. pneumoniae and S. viridans (n = 1; 2.6%). ESBL-producing Gram-negative bacteria were found only in gut microbiota, not in the wound isolates.
DISCUSSION
The digestive tract plays a crucial role in the development of antibacterial resistance through selection and multiplication of resistant bacteria in hospitals and in the community. It is also a place where exchange of resistance genes occurs and selection of resistant bacteria due to antibacterial treatments plays an important role (Carlet, 2012) . Since the 1980s, after introduction of cephalosporines in clinical practice, ESBL producers were discovered among Klebsiella spp. and Enterobacter spp. ESBL were encoded by the mutated genes of the plasmid-borne bla TEM and bla SHV wildtype penicillinase genes (Kliebe et al., 1985; Petit et al., 1990) . Apart from hospital-acquired infections, ESBL are present in non-outbreak situations, also in the community.
Despite the global dissemination of ESBL-producing bacteria Enterobacteriaceae (ESBL-E), there is a lack of guidelines on screening and isolation protocols of ESBL-E carriers in hospitals. Primary screening for ESBL bacteria colonisation is used for intensive care unit (ICU) patients, because of higher rates of outbreaks than in other wards (Woerther et al., 2013) .
Previous studies on the prevalence of ESBL-E in hospitalised patients in Latvia are limited (Paberza et al., 2007) . In that study of Paberza et al., the prevalence of ESBL-producing Klebsiella and E. coli was 37.7% and 6.0%, respectively, in gut microbiota. This differs from our study, as the respective prevalence was 88.8% and 13.2% in gut microbiota. To our knowledge, our study is the first attempt in Latvia to screen hospitalised patients for ESBL-producing bacteria in gut microbiota. The screening was done only for three months, so that data to be comparable to other countries. From these results it is clear that there is urgent need for further screening of patients for ESBL, to determine if the prevalence and tendency is tending to increase or decrease.
In our study 33.8 % (n = 46) of the studied patients were carried ESBL microbiota in the gastrointestinal tract. In comparison, in Europe the highest rate 11.6% was observed in Belgium in a geriatric unit (Schoevaerdts et al., 2012) .
The review by Woerther et al. (2013) shows that transmission of ESBL microbiota in Europe has increased from 2002 to 2011. The highest prevalence rates in the world have been reported from South-East Asia and China, where they reached nearly 70% in 2013 (Reuland et al., 2016) .
Our hypothesis was that the longer time a patient spends in the hospital, the greater is risk to gain a colonisation by gut ESBL. According to our data, nine of 14 (64.0%) patients who spent six to ten days at the hospital, gained ESBLpositive flora, and three of four patients who spent more than 25 days in hospital were positive. Our hypothesis was confirmed, as the duration of hospitalisation increased the risk of gaining ESBL-positive gut microbiota.
The largest group of nine patients had ESBL-producing microbiota, being the highest prevalence among other groups.
Comparing our results to other studies, where average duration of hospitalisation from the date of admission to date of a positive culture for ESBL-producing bacteria was 25 days with mean hospital stay 47 days, according to Rubio-Perez et al. 2012 . In a study by Shaihk et al. (2015) , mean duration of hospital stay was 5.63 days among patients gaining ESBL-producing bacteria, and a period of three days of hospital stay was found to be a significant risk factor for obtaining ESBL-producing bacteria. We cannot compare these results to our study, since duration of hospitalisation was different. However, it does appear that an increase in hospitalisation time longer than three days stay multiplies the risk for colonisation with ESBL microbiota. This was the limitation of our study, since patients did not stay in the hospital for more than on average 14 days, due to specificity of wards, etc. surgery and burns. Further studies are needed to find association between a longer period of stay in the hospital and ESBL-E carriage. Our study shows that relatively more ESBL-E-producing bacteria were detected, which might be explained by antimicrobial selection. It is known from other studies that ESBL bacteria carriers have a longer length of stay in the hospital due to an ESBL-E-producing bacterial infection or comorbidity (Willemsen et al., 2015) .
Interestingly, S. aureus 23.7% and CoNS 15.8% from patient wounds were found to be the predominant ESBLproducing bacteria. This finding differs from previous studies, where, according to the ECDC Surveillance 2013 report data, more than 50% of K. pneumoniae and 10-25% of E. coli clinically significant strains in Latvia produced ESBL (Hawser et al., 2010; Skuja et al., 2015) .
According to data from the European Antimicrobial Resistance Surveillance System (EARSS), 2.6% of E. coli and 1.7% of K. pneumoniae strains in Sweden were resistant to third-generation cephalosporins in 2010 (Sibhghatulla et al., 2015) . The percentage of isolates that express resistance to third-generation of cephalosporins was found to be lowest in Sweden (3.0%), Norway (3.6%) and Finland (5.1%) and highest in Bulgaria (22.9%), Slovakia (31.0%) and Cyprus (36.2%). E. coli strains resistant to fluoroquinolones were present in low numbers in Sweden (7.9%), Norway (9.0%) and Estonia (9.9%) while they were predominant in Italy (40.5%), Slovakia (41.9%) and Cyprus (47.4%) (Allocati et al., 2013) .
We were also interested to determine a correlation between the carriage of ESBL-producing bacteria in gut microbiota and the prevalence of those in wound infection. Another clinical study in Latvia showed that K. pneumoniae was mostly isolated from wounds (48.5%) and was the most frequently isolated ESBL-producing bacteria in all clinical cases (Skuja et al., 2015) .
It is known that wound infections caused by bacteria are most often associated with prolonged hospital stay and thus subsequent risk of acquiring multiple resistant organisms from medical devices and hospital environment (Idowu et al., 2011) .
Therefore, in our study the clinical material from wounds (namely, pus) was investigated in 26 patients and identified by culturing. However, none of the identified bacterial species from wounds were characterised as ESBL-producing bacteria.
Notably, our results for most frequently isolated species, namely, S. aureus 23.7% and CoNS 15.8%, revealed to be different from those of other studies, where Klebsiella species (88.88%) were the most common ESBL producers from the skin wound infections, E. coli (61.5%) and Pseudomonas species (100.0%) (Yasmin et al., 2015) .
The difference in the prevalence of ESBL-positive bacteria in wounds in our study compared to other studies can be explained by the relatively small number of ESBL-positive patients (n = 46) in our study. Our results indicate that there is no risk for ESBL-positive bacteria in wounds, but further studies are required. Evaluation of the data on ESBL prevalence in gut microbiota indicates that repeated hospitalisation is an important risk factor for gaining ESBL-E by a patient. There is an obvious need for molecular characterisation of ESBL-producing genes (CTX. TEM and SHV plasmid groups) encoded by plasmids (Caratolli, 2009; Canton et al., 2012; Liakopoulos et al., 2016) .
Data on faecal carriage with ESBLs in healthy individuals are lacking for most countries, but the rate has been estimated to be 10% in Asia and 5.5% in Spain. The geographical differences in the prevalence of ESBL microbiota in clinical cultures extend in proportion with healthy individuals colonised with ESBL-producing isolates (Tängdén et al., 2010) .
To our knowledge, no previous research has been made on the prevalence of ESBL-E carriage in the Latvian population, but this could be an additional source of resistant bacteria spread and the risk for patients during hospitalisation.
As an example, our previous studies of methicillin resistant S. epidermidis in the community showed that the prevalence of resistant species was 12.5% in the nasal cavity of healthy persons (Lîduma 2016) . The study of Mulki and co-authors (Mulki et al., 2017) showed that patients are likely to spread high loads of ESBL-producing bacteria in the environment. Additionally, in future studies it would be important to evaluate additional risk factors for gaining ESBL carriage, e.g., repeated hospitalisation or transfer, previous antibiotic treatment and catheterisation. This would provide better understanding on ESBL gain and spread risk factors in Latvian hospitals.
CONCLUSIONS
1. The inpatient colonisation with ESBL-producing bacteria is relatively high in Latvia.
2. The hospital environment is a promoting factor for ESBL prevalence in patients.
3. No correlation was found between the wound infection and gut colonisation with ESBL-producing Enterobacteriaceae.
